Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. (NASDAQ: VERU) is a late clinical-stage biopharmaceutical company advancing innovative therapies for cardiometabolic diseases, oncology, acute respiratory distress syndrome (ARDS), and sexual health. This page provides investors and stakeholders with timely updates on clinical trial progress, regulatory milestones, and strategic initiatives.
Access the latest Veru news, including press releases on drug development programs like enobosarm for muscle preservation during weight loss and sabizabulin for inflammatory conditions. Stay informed about earnings updates, partnership announcements, and scientific advancements across Veru's diversified pipeline.
All content is sourced directly from company communications and vetted financial news outlets. Bookmark this page for streamlined access to critical updates affecting Veru investment analysis and market positioning.
Veru Inc. (NASDAQ: VERU) reported a 6% increase in net revenues to $10.3 million for Q3 2020, driven by a 23% rise in U.S. prescription sales of FC2®. Gross profit for the quarter was 63%, with an operating loss narrowing to $1.4 million. Year-to-date revenues surged 34% to $30.8 million, buoyed by a remarkable 95% increase in FC2 sales. The company also received positive FDA input on the Phase 3 trial design for VERU-111, aiming for metastatic prostate cancer treatment, with plans to commence in Q1 2021. Investor conference call held today at 8 a.m. ET.
Veru Inc. (NASDAQ: VERU) has announced that VERU-111 has shown significant anti-inflammatory effects in vitro, targeting key cytokines involved in the cytokine storm related to COVID-19. In a University of Tennessee study, VERU-111 effectively reduced levels of TNFα, IL-1α, IL-1β, IL-6, and IL-8 by substantial percentages, indicating its potential for treating the severe respiratory syndrome. A Phase 2 clinical trial is currently enrolling 40 patients to evaluate its efficacy in preventing acute respiratory distress syndrome (ARDS) in high-risk COVID-19 patients.
Veru Inc. (NASDAQ: VERU) plans to release its fiscal 2020 third-quarter financial results on August 13, 2020, prior to the market opening. The company's management will conduct a conference call at 8 a.m. ET to discuss performance and answer questions. Veru is engaged in developing treatments for prostate cancer, including VERU-111 and VERU-100, with ongoing clinical studies. The company is also advancing its specialty pharmaceutical pipeline, including TADFIN for benign prostatic hyperplasia. The call will be available via webcast and archived for three months.
Veru Inc. (NASDAQ: VERU) announced that results from its Phase 1b/2 study of VERU-111, a novel treatment for metastatic castration-resistant prostate cancer, will be presented at the ESMO Virtual Congress 2020 on September 19-21, 2020. The study evaluates patients who have failed androgen receptor-targeting agents like enzalutamide. Enrollment for the ongoing Phase 2 study is nearing completion. Veru continues to advance its pipeline of products targeting unmet medical needs in urology and oncology.
Veru Inc. (NASDAQ: VERU) announced FDA regulatory clarity on the Phase 3 trial design for VERU-111, an oral treatment targeting metastatic castration-resistant prostate cancer. The FDA accepted the trial's focus on pre-chemotherapy patients and approved radiographic progression-free survival as a primary endpoint. This lowers the required sample size to approximately 200-300 participants. The final protocol submission is planned for Q4 2020, with a Phase 3 study anticipated to start in Q1 2021. The milestone signifies a significant step forward in addressing unmet medical needs in prostate cancer treatment.
Veru Inc. (NASDAQ: VERU) has been added to the Russell 2000® and Russell 3000® Indices, effective today, following Russell's annual reconstitution. This inclusion is expected to enhance visibility and attract investment. The Russell 2000 Index includes small-cap stocks representing about 10% of the total market cap of the Russell 3000 Index, which covers approximately 98% of the U.S. equity market. Veru focuses on developing treatments for prostate cancer, with several products in clinical trials and a growing portfolio in urology.
Veru Inc. (NASDAQ: VERU) has commenced its Phase 2 clinical trial for VERU-111, a microtubule depolymerization drug aimed at treating COVID-19. The trial will enroll 40 hospitalized patients at high risk for acute respiratory distress syndrome (ARDS). Patients will receive either VERU-111 or a placebo for 21 days. The drug has shown potential for inhibiting SARS-CoV-2 and alleviating severe inflammation related to the virus. The primary endpoint is the proportion of patients alive without respiratory distress by Day 29. Quick enrollment is anticipated due to rising COVID-19 cases.
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on oncology and urology, will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 9:30 a.m. ET. The presentation will cover the company's prostate cancer treatments, including VERU-111, which is currently in clinical trials for metastatic castration-resistant prostate cancer. Other pipeline products include Zuclomiphene citrate and VERU-100, targeting advanced prostate cancer. A webcast of the presentation will be available on their website for at least 90 days post-event.
Veru Inc. (NASDAQ: VERU) reported a significant 43% increase in net revenues, reaching $9.9 million for Q2 FY 2020, and a 61% rise in gross profit to $7.4 million. The gross margin improved to 75%. The company is progressing in its clinical trials, with positive Phase 1b results for VERU-111 in treating advanced prostate cancer and FDA clearance for a Phase 2 COVID-19 study. Operating loss narrowed to $0.3 million compared to $2.1 million last year. The results highlight strong growth in prescription sales and bolster Veru's position in oncology therapeutics.
Veru Inc. (NASDAQ: VERU) has received FDA approval to initiate a Phase 2 clinical trial for VERU-111, an oral microtubule depolymerization agent, targeting COVID-19 treatment. This trial will assess its efficacy in hospitalized patients at high risk for acute respiratory distress syndrome (ARDS). The trial will involve 40 subjects, comparing VERU-111 to a placebo over 21 days. Following its promising Phase 1b results in prostate cancer, this dual-action agent aims to combat both the virus and inflammatory responses associated with COVID-19.
